Inhibikase Therapeutics
3375 Spring Hill Parkway SE
Suite 811
Smyrna
Georgia
30080
United States
Tel: 917-494-0831
106 articles about Inhibikase Therapeutics
-
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
3/7/2024
Inhibikase Therapeutics, Inc. today announced that Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics, will present an update on the of the 201 Trial evaluating risvodetinib (“risvo”) at the 2024 AD/PD Meeting being held March 5-9, 2024 in Lisbon, Portugal.
-
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
2/28/2024
Inhibikase Therapeutics, Inc. announced preliminary outcomes of the Company’s discussion with the U.S. Food and Drug Administration on the path to approval of IkT-001Pro in blood and stomach cancers, the Company’s prodrug of the anticancer agent imatinib mesylate.
-
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
2/7/2024
Inhibikase Therapeutics, Inc. today announced preliminary outcomes of the Company’s discussion with the U.S. Food and Drug Administration (FDA) on the path to approval of IkT-001Pro in blood cancers, the Company’s prodrug of the anticancer agent imatinib mesylate.
-
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
1/29/2024
Inhibikase Therapeutics, Inc. today announced a publication of Phase 1 clinical studies with risvodetinib (“risvo”), a potential disease-modifying therapy for Parkinson’s disease and related disorders.
-
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
1/16/2024
Inhibikase Therapeutics, Inc. today announced that Joseph Frattaroli, Chief Financial Officer, plans to retire at the end of the first quarter of 2024.
-
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
12/19/2023
Inhibikase Therapeutics, Inc. today issued a Letter to Shareholders.
-
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
12/4/2023
Inhibikase Therapeutics, Inc. today announced the U.S. Food and Drug Administration has granted a pre-New Drug Application (pre-NDA) meeting to be held in January 2024 to discuss the requirements for approval of IkT-001Pro and to review the data establishing doses of IkT-001Pro bioequivalent to 400 mg and 600 mg imatinib mesylate.
-
Inhibikase Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
11/14/2023
Inhibikase Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023 and highlighted recent developments.
-
Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
11/7/2023
Inhibikase Therapeutics, Inc. announced that it will report financial results for the third quarter ended September 30, 2023, on Tuesday, November 14, 2023, after the close of U.S. markets.
-
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
10/16/2023
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company) today highlighted an analysis of eleven unblinded participants from the 201 Trial evaluating risvodetinib (IkT-148009) in untreated Parkinson’s disease.
-
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
10/4/2023
Inhibikase Therapeutics, Inc. today announced that risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Multiple System Atrophy (MSA).
-
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
9/20/2023
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders in response to recent price volatility.
-
Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib
8/24/2023
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company) today announced that it has developed a novel tablet formulation of IkT-148009, designed to improve drug exposure and overcome existing challenges related to patient use.
-
Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders - August 22, 2023
8/22/2023
Inhibikase Therapeutics, Inc. today announced that Milton Werner Ph.D., President and Chief Executive Officer of Inhibikase, will deliver two oral presentations at the International Congress of Parkinson's Disease and Movement Disorders. The event is being held in Copenhagen, Denmark, between August 27-31, 2023.
-
Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib
8/21/2023
Inhibikase Therapeutics, Inc. is evaluating new molecules with multiple mechanisms of action for c-Abl inhibition.
-
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
8/17/2023
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company") today announced the completion of its bioequivalence study of IkT-001Pro compared to 400 mg imatinib mesylate.
-
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
8/14/2023
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, reported financial results for the second quarter ended June 30, 2023 and highlighted recent developments.
-
Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
8/7/2023
Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023.
-
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
7/17/2023
Inhibikase Therapeutics, Inc. announced that it received written notice on July 17, 2023 from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC indicating that Inhibikase Therapeutics has regained full compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550, and that Inhibikase is in compliance with all applicable listing standards.
-
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
6/29/2023
Inhibikase Therapeutics, Inc. today announced that it will effect a 1-for-6 reverse stock split of its common stock.